Drug Repositioning

1. Auflage 2012
ISBN: 978-0-470-87827-9
Verlag: Wiley

Buch, Englisch, 498 Seiten, Format (B × H): 161 mm x 240 mm, Gewicht: 1361 g

With Viagra the most famous example, drug repositioning has been growing in importance for pharmaceutical companies seeking to reinvigorate development pipelines. This book provides a broad overview of drug repositioning including the business reasons and unique opportunities and challenges. Its coverage also presents a number of current and emerging technologies that are being applied, along with relevant case studies, as well as neglected diseases to consider. Pharmaceutical researchers will learn how to use drug repositioning techniques to increase the lifespan and applications of their drugs, and also decrease both costs and development time.

Autoren/Hrsg.

Barratt, Michael J

Frail, Donald E

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Pharmakologie, Toxikologie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Pharmazie
• Technische Wissenschaften Verfahrenstechnik | Chemieingenieurwesen | Biotechnologie Pharmazeutische Technologie
• Naturwissenschaften Chemie Chemie Allgemein Pharmazeutische Chemie, Medizinische Chemie

Inhaltsverzeichnis

Introduction
Michael Barratt and Donald Frail

Part 1. Drug Repositioning: Business Case, Strategies and Operational Considerations

1. Drug Repositioning: The Business Case and Current Strategies to Repurpose Shelved Candidates and Marketed Drugs
John Arrowsmith and Richard Harrison

2. Opportunities and challenges associated with developing additional indications for clinical development candidates and marketed drugs
Donald Frail and Michael Barratt

3. Clinical and operational considerations in repositioning marketed drugs and drug candidates
Damian O'Connell, David Sequeira and Maria Miller

4. Regulatory considerations and strategies for drug repositioning
Ken Phelps

Part 2. Application of Technology Platforms to Uncover New Indications and Repurpose Existing Drugs

5. Computational and Bioinformatic Strategies for Drug Repositioning
Richard Mazzarella and Craig Webb

6. Mining scientific and clinical databases to identify novel uses for existing drugs
Christos Andronis, Anuj Sharma, Spyros Deftereos, Vassilis Virvilis, Ourania Konstanti, Andreas Persidis and Aris Persidis

7. Predicting the polypharmacology of drugs: Identifying new uses through chemoinformatics, structural informatics and molecular modeling based approaches
Li Xie, Sarah Kinnings, Lei Xie and Philip Bourne

8. Systemic phenotypic screening for novel synergistic combinations: A new paradigm for repositioning existing drugs
Margaret Lee

9. Phenotypic in vivo screening to identify new, unpredicted indications for existing drugs and drug candidates
Michael Saporito, Christopher Lipinski and Andrew Reaume

10. Old Drugs Yield New Discoveries: Examples from the Prodrug, Chiral Switch and Site-Selective Deuteration Strategies
Adam Morgan, Bhaumik Pandya, Craig Masse and Scott Harbeson

Part 3. Academic and Non-Profit Initiatives & the Role of Alliances in the Drug Repositioning Industry

11. Repurposing Drugs for Tropical Diseases: Case Studies and Open-source Screening Initiatives
Curtis Chong

12. Drug Repositioning Efforts by Non-Profit Foundations

12.1 Repositioning Drugs for Leukemia and Lymphoma: Perspective From The Leukemia & Lymphoma Society
Louis DeGennaro, Aaron Schimmer, James Kasper and Richard Winneker

12.2 Repositioning drugs for Parkinson's disease: Perspective from the Michael J. Fox Foundation
Todd Sherer, Alison Urkowitz, and Kuldip Dave

12.3 Repositioning drugs for Polycystic Kidney Disease (PKD): Perspectives from the Polycystic Kidney Disease Foundation
Jill Panetta and John McCall

13. Business Development Strategies in the Repositioning Industry
Aris Persidis and Elizabeth Stark

14. A Case Study in Drug Repositioning: Sosei
Akinori Mochizuki and Makiko Aoyama